Chargement en cours...
The Prognostic Value of the Tumor Shrinkage Rate for Progression-Free Survival in Patients with Non-Small Cell Lung Cancer Receiving Gefitinib
BACKGROUND: The efficacy of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy can be measured based on the rate of treatment response, based on the Response Evaluation Criteria in Solid Tumors (RECIST) criteria or progression-free survival (PFS). However, there are some p...
Enregistré dans:
| Publié dans: | Tuberc Respir Dis (Seoul) |
|---|---|
| Auteurs principaux: | , , , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
The Korean Academy of Tuberculosis and Respiratory Diseases
2015
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4620323/ https://ncbi.nlm.nih.gov/pubmed/26508917 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4046/trd.2015.78.4.315 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|